News

There are currently no dietary guidelines for patients with MS and their at-risk relatives. And so far, dietary studies for MS patients have centered on vitamin D and obesity, but not overall diets.

For every hospital admission in the previous year, the odds of C. difficile infection increased by 14%, according to a recent study.

Six years after it was initially rejected by regulators, a new relapsing remitting multiple sclerosis drug has been approved for sale in Europe.

If approved, the drug will be the first and only single-dose oral therapy available or the condition.

Scientists now have a clearer understanding of how the protein NS5A gets around the body’s cellular defenses.

If approved, ABT-620 would become the first new treatment for endometriosis in more than a decade.

A study found that the demographic characteristics of patients who failed to initiate ART within 2 years of entering care were not as important as clinical factors.

Are asthma patients being mismanaged when treatment guidelines on specialist referrals are overlooked?

Five-year mortality rates decreased 7% for those who were part of the triple-screened group of the study.

The funds supplement a $12 million base given to the same state programs in July.

ALIS reduced the evidence of nontuberculous mycobacterial lung disease by 29% compared to 9% with guideline-based therapy alone.

No strokes were experienced by the apixaban group, compared to 6 in the warfarin arm of the study.

Alcohol-related disorders and mood disorders accounted for 6.8% of avoidable emergency department visits.

The rates of viral rebound in people with long-term viral suppression on first-line regimens have become "extremely low," according to a study.

Preschool children presenting to emergency departments for wheezing did not benefit from the addition of azithromycin to symptomatic treatment.

While the national split is a significant jump from previously reported rates, the degrees of the success vary in different parts of the country, Barry S. Zingman, MD, Medical Director, AIDS Center, Montefiore Health System, told MD Magazine.

Netherland researchers tracked instances of the C. difficile therapy to as far back as 300 AD, in China.

A 10-year follow-up of patients with severe asthma finds persistent illness remains difficult to treat.

Subcutaneous monoclonal antibodies could change the stagnant scope of migraine treatment.

Cleveland Clinic physicians weigh in on their best methods for maintaining a good doctor-patient relationship.

The drug, produced by Sanofi, was granted approval based on the physiochemical, non-clinical, and clinical similarity to another, already approved insulin lispro injection.

Stay connected and up-to-date in health care news with the Connected Clinician top stories of the week for the week of August 28.

An integrated care program successfully extended HCV treatment to patients not well served by traditional outreach efforts.

Researchers from Loyola Medicine retrospectively studied 100 vancomycin taper and pulse treatment patients treated for recurrent C. difficile infection over the span of 5 years.

Rivaroxaban plus aspirin showed a 31% reduction in major cardiovascular events for PAD patients.

Researchers found in data of 1,868 people that women who inject drugs are at a 38% greater risk of contracting HCV than men who inject drugs.

In a phase 2 trial, MDMA reduced PTSD in 68% of patients after a 12-months period.

The C3 inhibitor showed a 29% reduction in geography atrophy over a 1-year period.

It becomes only the second FDA-approved drug for the movement disorder, following valbenazine (Ingrezza) earlier this year.

The Section Head of Hepatology at the Cleveland Clinic discusses current issues in treating hepatitis, and what's still to come in possibly eradicating the disease.